Atrandi Biosciences, a Vilnius, Lithuania-based life sciences firm advancing new single-cell evaluation know-how, raised $25M in Collection A funding.
The spherical was led by Lux Capital, with participation from Vsquared Ventures, Practica Capital, Metaplanet and GRIDS Capital.
The corporate intends to make use of the funds to speed up its growth into the U.S. market, assist the expansion of its semi-permeable capsule (SPC) know-how, and advance new product improvement to allow scientific discoveries.
Led by CEO Juozas Nainys, Atrandi Biosciences is empowering single-cell evaluation with its patented semi-permeable capsule (SPC) know-how, enabling single-cell multiomics. By simplifying complicated workflows, it accelerates discoveries in mobile heterogeneity, clonal evolution, microbiome range, microbial ecology, and extra.
Its flagship merchandise embrace:
- Flux Microfluidic Machine – A platform constructed for high-throughput single-cell isolation into Semi-Permeable Capsules (SPCs) on the push of a button.
- Onyx Droplet Generator – A microfluidic platform designed for high-throughput single-cell and single-molecule purposes.
- Styx Excessive-Throughput Screening Platform – A screening platform designed for environment friendly fluorescence-activated droplet sorting.
FinSMEs
19/02/2025
